Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#124 / 124 Total
SLRN - Acelyrin Inc - Stock Price Chart
TickerSLRN [NASD, RUT]
CompanyAcelyrin Inc
CountryUSA
IndustryBiotechnology
Market Cap459.13MEPS (ttm)-3.06
P/E-EPS this Y45.60%
Forward P/E-EPS next Y28.97%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.81EPS Q/Q-222.51%
Dividend-Sales Q/Q-
Insider Own35.41%Inst Own77.36%
Insider Trans-0.03%Inst Trans-
Short Float11.16%EarningsAug 13/a
Analyst Recom1.86Target Price11.40
Avg Volume1.11M52W Range3.36 - 11.23
Sep-12-24 01:30AM Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc (GuruFocus.com)
Sep-10-24 07:00AM ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery (GlobeNewswire)
Aug-22-24 07:00AM ACELYRIN, INC. to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.42%
Aug-13-24 04:00PM ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results (GlobeNewswire) -14.71%
03:37AM Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now? (Insider Monkey)
Aug-06-24 04:30PM ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 (GlobeNewswire)
Jun-05-24 07:00AM ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 (GlobeNewswire)
May-29-24 07:00AM ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 (GlobeNewswire)
May-15-24 11:54AM SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 08:01AM ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones (GlobeNewswire)
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Becker Daniel J.DirectorJul 17 '24Sale6.86172,999Jul 19 06:18 PM
Lin Shao-LeeChief Executive OfficerApr 01 '24Sale6.639,96166,0241,577,374Apr 03 06:18 PM
Lin Shao-LeeChief Executive OfficerFeb 20 '24Sale7.6015,701119,4031,587,335Feb 22 07:04 PM
Lin Shao-LeeChief Executive OfficerJan 02 '24Sale7.4110,69179,1881,603,036Jan 04 06:09 PM
1⋯8910111213
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.